Rafael Fonseca, MD

Cote J et al. First line treatment of newly diagnosed transplant ineligible multiple myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium. Blood Cancer J 2023;23(5):340-54. Abstract

Gay F et al. Results of the phase III randomized Iskia trial: Isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. ASH 2023;Abstract 4.

Pasvolsky O at el. Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission. Am J Hematol 2023;98(2):E35-7. Abstract

Sonneveld P et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2023;390:301-13. Abstract

María-Victoria Mateos, MD

Cohen YC et al. First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM). ASCO 2023;Abstract 8002.

Dholaria BR et al. Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results. ASCO 2023;Abstract 8003.

Matous JV et al. Talquetamab + pomalidomide in patients with relapsed/refractory multiple myeloma: Safety and preliminary efficacy results from the phase 1b MonumenTAL-2 study. ASH 2023;Abstract 1014.

Schinke CD et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM). ASCO 2023;Abstract 8036.

Touzeau C et al. Pivotal phase 2 MONUMENTAL-1 results of talquetamab (TAL), a GPRC5DXCD3 bispecific antibody (BSAB), for relapsed/refractory multiple myeloma (RRMM). EHA 2023;Abstract S191.

Elizabeth O'Donnell, MD

Martin T et al. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized phase 3 study. Blood Cancer J 2023;13(1):72. Abstract

Richardson PG et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): Follow-up analysis of a randomised, phase 3 study. Lancet Oncol 2022;23(3):416-27. Abstract

Schiller G et al. How thinly can one slice the AML diagnostic pie? Blood 2022;140(12):1330-1. Abstract